Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Everolimus, ATC L04AH02 für die Zeit 01.02.2026 - 31.01.2028 (zzgl. Verlängerungsoption 1x12 Monate)

Worth a closer look

• § 130a Abs. 8 SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount agreements for medicinal products to be charged to the statutory health insurance funds.
• The DAK-Gesundheit assumes that this procedure does not fall within the scope of cartel procurement law due to a lack of selection decision and thus the non-discriminatory access for all pharmaceutical companies.
• The contract documents are available for download via the online portal www.dtvp.de/center under the link named in 5.1.11.
• The offer is to be submitted in text form as an electronic offer via email.
• The publication is made using the form for open procedures. As already clearly stated, this is such a non-exclusive procedure - the notice had to be used for technical reasons as there is no suitable form for approval procedures.